Phenotype-genotype correlation in multiple primary lung cancer patients in China

Yang, Yang; He, Wenxin; Jiang, Chao; Zhou, Xiao; Song, Xiao; Zhu, Junjie; Fei, Ke; Cao, Weijun; Jiang, Gening

doi:10.1038/srep36177

Cited by 21 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, the KRAS mutation and EGFR were considered to be exclusive genes. Indeed, KRAS and EGFR were only found in <2% of NSCLC patients [ 82 , 83 , 84 , 85 ]. Moreover, the KRAS mutation was observed only in a mouse model, unlike in tissue samples obtained from patients with acquired resistance to first- and second-generation EGFR-TKIs [ 15 , 23 , 86 , 87 ].…”

Section: Acquired Resistancementioning

confidence: 99%

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Nagano

Tachihara

Nishimura

2018

Cells

217

188

View full text Add to dashboard Cite

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer (NSCLC). First-generation EGFR-TKIs (e.g., gefitinib and erlotinib) or second-generation EGFR-TKIs (e.g., afatinib and dacomitinib) are effective for the treatment of EGFR-mutated NSCLC, especially in patients with EGFR exon 19 deletions or an exon 21 L858R mutation. However, almost all cases experience disease recurrence after 1 to 2 years due to acquired resistance. The EGFR T790M mutation in exon 20 is the most frequent alteration associated with the development of acquired resistance. Osimertinib—a third-generation EGFR-TKI—targets the T790M mutation and has demonstrated high efficacy against EGFR-mutated lung cancer. However, the development of acquired resistance to third-generation EGFR-TKI, involving the cysteine residue at codon 797 mutation, has been observed. Other mechanisms of acquired resistance include the activation of alternative pathways or downstream targets and histological transformation (i.e., epithelial–mesenchymal transition or conversion to small-cell lung cancer). Furthermore, the development of primary resistance through overexpression of the hepatocyte growth factor and suppression of Bcl-2-like protein 11 expression may lead to problems. In this report, we review these mechanisms and discuss therapeutic strategies to overcome resistance to EGFR-TKIs.

show abstract

Section: Acquired Resistancementioning

confidence: 99%

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Nagano

Tachihara

Nishimura

2018

Cells

217

188

View full text Add to dashboard Cite

show abstract

“…Because of the intratumoral heterogeneity cannot be avoided in PCR or DNA sequencing analysis, the diagnosis of SMPLC cannot completely rely on molecular genetic characteristics. However, some studies still show that there were different gene mutations in different lesions of the same patient, and molecular gene detection can be used for the diagnosis of SMPLC [4,[21][22].…”

Section: Discussionmentioning

confidence: 99%

What are the Survival Factors in Surgically Resected Synchronous Multiple Primary Lung Cancers: A Retrospective Study

Wang

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: With the popularization of high-resolution computed tomography (HRCT), the detection rate of synchronous multiple primary lung cancer (SMPLC) is increasing. We retrospectively analyzed the surgical results of SMPLC patients in our hospital to determine the best treatment for SMPLC.Methods: A total of 90 SMPLC patients met the diagnostic criteria underwent complete resection and lymph node dissection or sampling without any preoperative induction therapy in the Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University. We analyzed the postoperative survival rate, and further studied the relationship between survival rates and sex, age, preoperative symptoms, tumor location, tumor number, tumor size, surgical type, surgical frequency, histopathologic types, vascular infiltration, visceral pleural invasion and postoperative therapy.Results: Among 90 patients, the 1- and 3-year disease free survival (DFS) rates were 97.0% and 76.7% while the 1- and 3-year overall survival (OS) rates were 98.81% and 82.35%. Vascular infiltration (HR=402.46, p=0.005) and postoperative chemotherapy (HR>1000, p<0.001) were independent risk factors for DFS, while only postoperative chemotherapy (HR=184.10, p=0.002) was an independent risk factor for OS.Conclusions: First, SMPLC is different from intrapulmonary metastasis and its clinical stage is also different from the 8th (2015) edition TNM classification for lung cancer. Second, when pulmonary function permits, surgery (complete resection and lymph node dissection) is a significantly beneficial treatment for patients with SMPLC. Third, for early stage SMPLC patients, vascular infiltration and postoperative chemotherapy are harmful to the survival.

show abstract

“…20,21 Both EGFR and RAS mutations contribute to the development of NSCLC. 22,23 KRAS mutations are rare in squamous cell carcinoma of the lung, but may be found in approx. 15-25% of lung adenocarcinomas.…”

Section: The Effects Of Genetic Factors On the Development Of Lung Camentioning

confidence: 99%

Multiple primary lung cancer: A literature review

Romaszko¹,

2018

View full text Add to dashboard Cite

Nowadays, lung cancer is a leading cause of death in both men and women worldwide. There is no clear explanation for its mortality rate. However, it is already known that genetic and environmental factors as well as oncological treatment are involved. As the incidence of lung cancer soars, the number of patients diagnosed with multiple primary lung cancers (MPLC) is also rising. While differentiating between MPLC and intrapulmonary metastasis of lung cancer is important for treatment strategy and prognosis, it is also quite complicated, particularly in the cases with similar histologies. It is also important not to delay the diagnosis. The aim of this paper was to discuss MPLC in general, and the differentiation between MPLC and intrapulmonary lung cancer metastasis in particular. Based on a review of statistical data and the current literature, we discuss the diagnostic criteria and the molecular, genetic and radiographic methods used to distinguish between MPLC and intrapulmonary metastases.

show abstract

Phenotype-genotype correlation in multiple primary lung cancer patients in China

Cited by 21 publications

References 32 publications

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

What are the Survival Factors in Surgically Resected Synchronous Multiple Primary Lung Cancers: A Retrospective Study

Multiple primary lung cancer: A literature review

Contact Info

Product

Resources

About